Categories: News

UfiSpace Unveils AIOptimized 1.6T Open Networking Portfolio at MWC Barcelona 2026

BARCELONA, Spain, March 2, 2026 /PRNewswire/ — UfiSpace, a leader in open networking solutions, today launched its AI-optimized 1.6T networking portfolio at MWC Barcelona 2026 (Hall 5, Stand 5A61). The portfolio addresses the scale, performance, and security demands of large-scale AI deployments with the S9331-64HO AI fabric switch and the S9630-32HO secure aggregation platform.

- Advertisement -

As AI infrastructure shifts toward hyperscale architectures, proprietary network designs often constrain growth and increase costs. UfiSpace’s open networking model enables capacity expansion aligned with AI workload demand, helping operators optimize investment while maintaining architectural flexibility.

- Advertisement -

High-Performance AI Fabric and Secure Transport

- Advertisement -

The S9331-64HO targets AI backend fabric requirements. Built on the Broadcom® Tomahawk 6 chipset, the system delivers 102.4 Tbps of switching capacity to support dense GPU clusters. Advanced traffic-management capabilities, including Adaptive Routing and congestion control, are designed to shorten Job Completion Time (JCT), improve compute efficiency, and accelerate AI training cycles.

- Advertisement -

The S9630-32HO extends the AI fabric to the transport layer. Powered by the Broadcom® Qumran 4D chipset, the platform provides line-rate MACsec and IPsec encryption, enabling secure aggregation without performance trade-offs. When deployed with OpenZR+ optics, it supports transmission distances of up to 400 kilometers, addressing requirements for AI Data Center Interconnect (DCI) and backbone modernization across distributed AI infrastructure.

- Advertisement -

Sustainability and the 1.6T Roadmap

- Advertisement -

As 1.6T networking platforms deliver unprecedented bandwidth and performance, they also introduce significant thermal and power challenges. UfiSpace is showcasing AI-ready networking solutions at MWC Barcelona, designed to address these constraints in high-density network deployments. The company will demonstrate advanced liquid-cooling solutions at OFC 2026 in Los Angeles (March 17–19), engineered to enhance Power Usage Effectiveness (PUE) and support the thermal demands of next-generation 1.6T optical networking interfaces.

- Advertisement -

END OF ANNOUNCEMENT

- Advertisement -

About UfiSpace
UfiSpace is a leading provider of open networking solutions for telecommunications, cloud service providers, and hyperscale data centers. By leveraging merchant silicon and disaggregated architectures, UfiSpace enables its customers to build more agile, scalable, and cost-effective next-generation networks.

- Advertisement -

Follow us on our social media channels: LinkedIn, Facebook, and YouTube

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/ufispace-unveils-aioptimized-1-6t-open-networking-portfolio-at-mwc-barcelona-2026–302695279.html

- Advertisement -

Recent Posts

FemiCore (Official Website & Authenticity Notice 2026) Counterfeit Risks and What Consumers Should Know

New York City, NY, June 13, 2026 (GLOBE NEWSWIRE) -- The women's health supplement market…

3 hours ago

Hitch Open Ping-Pong Embodied (HOPE) AI Challenge Joins the 2026 World Humanoid Robot Games, Seeding Advanced Physical AI Against Human Performance

BEIJING, June 13, 2026 (GLOBE NEWSWIRE) -- The 2026 Hitch Open Ping-Pong Embodied AI Challenge…

3 hours ago

Crypto News Today: AlphaPepe Unveils AlphaSwap Early Access as Bitcoin Price Prediction Eyes $250,000

MONACO, June 12, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after…

3 hours ago

Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City

MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies [NSE: HEXT], a…

5 hours ago

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI…

6 hours ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

June 13, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc. Data from HAELO Phase 3…

6 hours ago